Martin Schuler
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich B, Kurbacher C, Fuchs R, Tesch H, Krabisch P, Huober J, Kümmel S, Brucker S, Janni W, Schneeweiss A, Schuler M, Fehm T, Luftner D, Quiering C, Voges C, Kreuzeder J, Reinisch M. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. Eur J Cancer 2023; 198:113480.
Dec 15, 2023Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Dec 15, 2023Eur J Cancer 2023; 198:113480
Fasching Peter Andreas, Decker Thomas, Hartkopf Andreas D, Nusch Arnd, Heinrich Bernhard J, Kurbacher Christian M, Fuchs Roswitha, Tesch Hans, Krabisch Petra, Huober Jens, Kümmel Sherko, Brucker Sara Y, Janni Wolfgang, Schneeweiss Andreas, Schuler Martin, Fehm Tanja N, Luftner Diana, Quiering Claudia, Voges Claudia, Kreuzeder Julia, Reinisch Mattea
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Schuler M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Schostak M, Park S, Cho B, Sayehli C, Navarro A, Soo R, Richly H, Cassier P, Tai D, Penel N, Nogova L, Jörger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019
Aug 9, 2019Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Aug 9, 2019Lancet Oncol 2019
Schuler Martin, Gajate Pablo, Cathomas Richard, Rajagopalan Prabhu, Grevel Joachim, Bender Sebastian, Boix Oliver, Nogai Hendrik, Ocker Matthias, Ellinghaus Peter, Schostak Martin, Park Se Hoon, Cho Byoung Chul, Sayehli Cyrus Michael, Navarro Alejandro, Soo Ross A, Richly Heike, Cassier Philippe Alexandre, Tai David, Penel Nicolas, Nogova Lucia, Jörger Markus
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression
Kalkavan H, Rathbun J, Cannon P, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang P, Drexler I, von Laer D, Wollmann G, Sharma P, Kasper S, Helfrich I, Pandyra A, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle P, Lang K. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun 2017; 8:14447.
Mar 1, 2017Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression
Mar 1, 2017Nat Commun 2017; 8:14447
Kalkavan Halime, Rathbun Jessica, Cannon Paula M, Scheu Stefanie, Bauer Jens, Chauhan Jagat, Häussinger Dieter, Willimsky Gerald, Löhning Max, Schadendorf Dirk, Brandau Sven, Schuler Martin, Lang Philipp A, Drexler Ingo, von Laer Dorothee, Wollmann Guido, Sharma Piyush, Kasper Stefan, Helfrich Iris, Pandyra Aleksandra A, Gassa Asmae, Virchow Isabel, Flatz Lukas, Brandenburg Tim, Namineni Sukumar, Heikenwalder Mathias, Höchst Bastian, Knolle Percy A, Lang Karl S
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015; 10:1451-7.
Oct 1, 2015Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Oct 1, 2015J Thorac Oncol 2015; 10:1451-7
Gautschi Oliver, Kerjouan Mallorie, Michels Sebastian, Pall Georg, Rothschild Sacha, Schmid-Bindert Gerald, Scheffler Matthias, Veillon Rémi, Wannesson Luciano, Diebold Joachim, Zalcman Gérard, Filleron Thomas, Huret Benjamin, Curioni-Fontecedro Alessandra, Milia Julie, Cabarrou Bastien, Bluthgen Marie-Virginia, Besse Benjamin, Smit Egbert F, Wolf Juergen, Peters Solange, Früh Martin, Koeberle Dieter, Oulkhouir Youssouf, Schuler Martin, Mazières Julien